Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this ancillary study on the FoxTreg cohort, the study investigators will select variables to input and thus develop two models (Linear Discriminant Analysis and Decision Tree). The aim of this study is to validate the method in terms of repeatability, reproducibility, control of pre-analytical conditions and sample conservation, to complete the screening of IgA glycosylation in individuals of the FoxTreg cohort and to refine the glycopeptide signature to predict renal involvement.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Acute Rheumatoid Purpura |
| ||
| Rheumatoid Purpura in Remission |
| ||
| Controls | Without infection, inflammatory or auto-immune pathology |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mass Sepctrometry | Other | Mass spectrometry (LC/MS) of purified immunoglobulins |
|
| Measure | Description | Time Frame |
|---|---|---|
| Glycopeptide signature of serum from children with Rheumatoid Purpura | Mass spectrometry to identify the glycopeptides present and their level | Day 0 |
| Measure | Description | Time Frame |
|---|---|---|
| Repeatability of mass spectrometry in measuring glycopeptide signature | Mass spectrometry to identify the glycopeptides present and their level | Day 0 |
| Reproducibility of mass spectrometry in measuring glycopeptide signature |
Not provided
Inclusion Criteria:
Patient sera from biobank of the FoxTreg study (NCT02317133)
Not provided
Not provided
This is an ancillary study on the patient biobank of the FoxTreg study (NCT02317133). All these patients had given their consent for blood sampling and the conservation of biological samples within the Biological Resources Center (CRB) of Nîmes. A total of 97 patients were recruited, forming three groups:
For this "FoxIgA-2020" study, only sera collected from these patients not analyzed in the "FoxIgA" study will be used.
Thus 52 samples will be analyzed for the FoxIgA-2020 study:
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tu Anh TRAN | CHU de Nimes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU de Montpellier | Montpellier | France | ||||
| CHU de Nimes |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20413568 | Background | Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010 May;69(5):798-806. doi: 10.1136/ard.2009.116657. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples already in existence
Mass spectrometry to identify the glycopeptides present and their level
| Day 0 |
| Control of conservation of samples for measuring glycopeptide signature | Mass spectrometry to identify the glycopeptides present and their level | Day 0 |
| Glycopeptide signature of serum from all patients of the cohort | Mass spectrometry to identify the glycopeptides present and their level | Day 0 |
| Difference between a normally glycosylated IgA and an IgA with GalNac polymer in Rheumatoid Purpura patients with / without renal impairment versus controls | Mass spectrometry to identify the glycopeptides present and their level | Day 0 |
| Number of subjects with IgA glycosylation abnormalities in Rheumatoid Purpura patient population with renal impairment polymer in Rheumatoid Purpura patients with / without renal impairment versus controls | Mass spectrometry of IgA | Day 0 |
| Percentage of subjects with IgA glycosylation abnormalities in Rheumatoid Purpura patient population with renal impairment polymer in Rheumatoid Purpura patients with / without renal impairment versus controls | Mass spectrometry of IgA | Day 0 |
| Number of subjects with IgA glycosylation abnormalities in each group | Mass spectrometry of IgA | Day 0 |
| Percentage of subjects with IgA glycosylation abnormalities in each group | Mass spectrometry of IgA | Day 0 |
| Serum immunoglobulin levels in patients with acute Rheumatoid Purpura and in remission | Mass spectrometry of immunoglobulins IgA, IgM and IgG (g/L) | Day 0 |
| Quantification of blood cell lines in patients with acute Rheumatoid Purpura and in remission. | Blood cell lines, particularly Treg and Breg (number/mm3) | Day 0 |
| Serum cytokine levels in patients with acute Rheumatoid Purpura and in remission | pg/ml of TGF-β, IL-1, IL-6, TNF-α, IL-8, IL-10 and IL-17 | Day 0 |
| Bacterial Translocation in patients with Rheumatoid Purpura | Plasma levels of 16S rDNA (copies/µl) | Day 0 |
| Plasma levels of LBP in patients with Rheumatoid Purpura | µg/ml | Day 0 |
| Plasma levels of CD14s in patients with Rheumatoid Purpura | µg/ml | Day 0 |
| Bacterial diversity in the gut microbiota in patients with Rheumatoid Purpura | Diversity Index | Day 0 |
| Nîmes |
| France |
| ID | Term |
|---|---|
| D011695 | IgA Vasculitis |
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| ID | Term |
|---|---|
| D014657 | Vasculitis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D011693 | Purpura |
| D001778 | Blood Coagulation Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D020141 | Hemostatic Disorders |
| D006474 | Hemorrhagic Disorders |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D007105 | Immune Complex Diseases |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012877 | Skin Manifestations |
| D012816 | Signs and Symptoms |
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
Not provided
Not provided